Harvard Bioscience (NASDAQ:HBIO) Stock Crosses Below Two Hundred Day Moving Average of $4.50

Harvard Bioscience, Inc. (NASDAQ:HBIO)’s share price crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $4.50 and traded as low as $4.15. Harvard Bioscience shares last traded at $4.44, with a volume of 192,772 shares changing hands.

Harvard Bioscience Price Performance

The business has a fifty day moving average of $4.37 and a 200 day moving average of $4.50. The company has a current ratio of 1.85, a quick ratio of 0.92 and a debt-to-equity ratio of 0.42.

Harvard Bioscience (NASDAQ:HBIO) last posted its quarterly earnings results on Thursday, March 7th. The medical instruments supplier reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). The company had revenue of $28.15 million during the quarter, compared to analyst estimates of $27.80 million. Harvard Bioscience had a negative net margin of 3.04% and a positive return on equity of 2.75%. As a group, equities analysts expect that Harvard Bioscience, Inc. will post 0.14 EPS for the current fiscal year.

Institutional Investors Weigh In On Harvard Bioscience

Several hedge funds and other institutional investors have recently made changes to their positions in the business. BNP Paribas Arbitrage SA increased its position in Harvard Bioscience by 47.6% during the second quarter. BNP Paribas Arbitrage SA now owns 9,920 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 3,200 shares during the period. Prudential Financial Inc. purchased a new position in shares of Harvard Bioscience in the 2nd quarter valued at approximately $37,000. Public Employees Retirement System of Ohio purchased a new position in shares of Harvard Bioscience in the 3rd quarter valued at approximately $40,000. Barclays PLC purchased a new position in shares of Harvard Bioscience in the 2nd quarter valued at approximately $43,000. Finally, Lazard Asset Management LLC grew its stake in shares of Harvard Bioscience by 230.5% in the 1st quarter. Lazard Asset Management LLC now owns 7,120 shares of the medical instruments supplier’s stock valued at $44,000 after purchasing an additional 4,966 shares during the last quarter. Institutional investors and hedge funds own 80.87% of the company’s stock.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.